Mometasone Teva (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. This binding alters gene transcription, decreasing the release of inflammatory mediators such as cytokines and prostaglandins. The result is reduced vascular permeability, edema, and immune cell infiltration, which together lessen nasal inflammation and symptom severity.

The prescribed dose of Mometasone Teva is determined by a healthcare professional based on the patient’s age, severity of symptoms, and clinical response. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of administration.

Safety data for mometasone furoate in pregnancy and lactation are limited. Physicians generally weigh the potential benefits against possible risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss their situation with a healthcare provider to determine if the medication is appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Mometasone Teva is a high‑potency, once‑daily nasal corticosteroid with a favorable safety profile when used as directed. Compared with lower‑potency options such as fluticasone, mometasone often provides comparable or greater symptom control with a similar incidence of local side effects, making it a preferred choice for moderate to severe allergic rhinitis and nasal polyps.

Store Mometasone Teva at temperatures below 25 °C (77 °F) in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight. Keep the spray bottle tightly closed when not in use to maintain sterility and potency.

Mometasone Teva is administered as a nasal spray. The patient gently shakes the bottle, primes it if required, and then inserts the nozzle into each nostril. The prescribed number of sprays is delivered while breathing in gently, and the patient should avoid blowing the nose for a few minutes after use.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions (anaphylaxis), ocular complications such as increased intra‑ocular pressure or cataracts, and systemic adrenal suppression with prolonged high‑dose use. Patients should report any unusual symptoms, such as persistent nosebleeds, vision changes, or severe irritation, to their healthcare provider promptly.

Mometasone Teva should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with untreated bacterial, fungal, or viral infections of the nasal passages until the infection has been resolved.